E-LIB Suche - Ergebnisse für: Kotapati, Srividya

1

Real‐World nivolumab dosing patterns and safety outcomes in..:

Samlowski, Wolfram ; Robert, Nicholas J. ; Chen, Liwei...
Cancer Medicine. 12 (2022) 3 - p. 2378-2388 , 2022

Link: https://doi.org/10.1002/..

2

Heterogeneity in Survival with Immune Checkpoint Inhibitors..:

Federico Paly, Victoria ; Kurt, Murat ; Zhang, Lirong...
MDM Policy & Practice. 7 (2022) 1 - p. 238146832210896 , 2022

Link: https://doi.org/10.1177/..

3

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Tre..:

Baker, Timothy ; Johnson, Helen ; Kotapati, Srividya...
PharmacoEconomics - Open. 6 (2022) 5 - p. 697-710 , 2022

Link: https://doi.org/10.1007/..

4

Long-term real-world experience with ipilimumab and non-ipi..:

Dalle, Stéphane ; Mortier, Laurent ; Corrie, Pippa...
BMC Cancer. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

5

Indirect treatment comparison of nivolumab versus placebo a..:

Weber, Jeffrey S. ; Ascierto, Paolo A. ; Middleton, Mark R....
European Journal of Cancer. 158 (2021) - p. 225-233 , 2021

Link: https://doi.org/10.1016/..

6

Comparative efficacy and safety of adjuvant nivolumab versu..:

Toor, Kabirraaj ; Middleton, Mark R. ; Chan, Keith...
BMC Cancer. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

7

Evaluating the potential of relapse-free survival as a surr..:

Coart, Elisabeth ; Suciu, Stefan ; Squifflet, Pierre...
European Journal of Cancer. 137 (2020) - p. 171-174 , 2020

Link: https://doi.org/10.1016/..

8

Indirect treatment comparison of nivolumab versus placebo f..:

Hemstock, Matthew ; Amadi, Adenike ; Kupas, Katrin...
European Journal of Cancer. 132 (2020) - p. 176-186 , 2020

Link: https://doi.org/10.1016/..

9

Healthcare cost comparison analysis of nivolumab in combina..:

Potluri, Ravi ; Ranjan, Sandip ; Bhandari, Hitesh...
Experimental Hematology & Oncology. 8 (2019) 1 - p. , 2019

Link: https://doi.org/10.1186/..

10

Modelling Survival of Patients Treated with Adjuvant Nivolu..:

Batteson, Rachael ; Hart, Rose ; Hemstock, Matthew...
PharmacoEconomics - Open. 4 (2019) 2 - p. 343-351 , 2019

Link: https://doi.org/10.1007/..

11

Societal preferences for adjuvant melanoma health states: U..:

Middleton, Mark R. ; Atkins, Michael B. ; Amos, Kaitlan...
BMC Cancer. 17 (2017) 1 - p. , 2017

Link: https://doi.org/10.1186/..

12

Patient and Physician Preferences for Treating Adjuvant Mel..:

Beusterien, Kathleen ; Middleton, Mark R. ; Wang, Peter Feng...
Journal of Cancer Therapy. 8 (2017) 1 - p. 37-50 , 2017

Link: https://doi.org/10.4236/..

13

Health-related quality of life results from the phase III C..:

Schadendorf, Dirk ; Larkin, James ; Wolchok, Jedd...
European Journal of Cancer. 82 (2017) - p. 80-91 , 2017

Link: https://doi.org/10.1016/..

14

Relapse-Free Survival as a Surrogate for Overall Survival i..:

Suciu, Stefan ; Eggermont, Alexander M M ; Lorigan, Paul...
JNCI: Journal of the National Cancer Institute. 110 (2017) 1 - p. 87-96 , 2017

Link: https://doi.org/10.1093/..

15

Real‐world treatment practice in patients with advanced mel..:

Middleton, Mark R. ; Dalle, Stéphane ; Claveau, Joel...
Cancer Medicine. 5 (2016) 7 - p. 1436-1443 , 2016

Link: https://doi.org/10.1002/..